Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | UCHL3 | P15374 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.35 |
| ▸ | DNTT | P04053 | 1/20 | 0.34 |
| ▸ | F13A1 | P00488 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.33 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20792223 | 1.00 | PPARG (0.43) | PPARGPPARDPPARATRPA1NR4A2 | |
| SCHEMBL12034625 | 1.00 | PPARG (0.43) | PPARGPPARDPPARATRPA1NR4A2 | |
| SCHEMBL11866056 | 0.86 | PPARG (0.61) | PPARGPPARDPPARATRPA1NR4A2 | |
| SCHEMBL11866044 | 0.86 | PPARG (0.61) | PPARGPPARDPPARATRPA1NR4A2 | |
| SCHEMBL21631706 | 0.78 | TRPA1 (0.59) | PPARGPPARDPPARATRPA1NR4A2 | |
| SCHEMBL11800847 | 0.77 | PPARG (0.67) | PPARGPPARDPPARATRPA1NR4A2 | |
| SCHEMBL15287190 | 0.77 | PPARG (0.67) | PPARGPPARDPPARATRPA1NR4A2 | |
| SCHEMBL17451520 | 0.77 | PPARG (0.67) | PPARGPPARDPPARATRPA1NR4A2 | |
| SCHEMBL11866575 | 0.76 | DNTT (0.44) | PPARGPPARDPPARATRPA1NR4A2 | |
| SCHEMBL11872504 | 0.73 | MAPT (0.53) | PPARGPPARDPPARATRPA1NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680327-B2 | Methods for manufacturing tetranor-prostaglandin D, J, E, A and F metabolites | CAYMAN CHEMICAL COMPANY, INCORPORATED (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680327-B2 | Methods for manufacturing tetranor-prostaglandin D, J, E, A and F metabolites | CAYMAN CHEMICAL COMPANY, INCORPORATED (US) | 2014-03-25 | — | — | US | disclosed |
| US-20120041229-A1 | METHODS FOR MANUFACTURING TETRANOR-PROSTAGLANDIN D, J, E, A AND F METABOLITES | CAYMAN CHEMICAL COMPANY, INCORPORATED (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120041229-A1 | METHODS FOR MANUFACTURING TETRANOR-PROSTAGLANDIN D, J, E, A AND F METABOLITES | CAYMAN CHEMICAL COMPANY, INCORPORATED (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120021437-A1 | TETRANOR-PGDM/PGJM SPECIFIC IMMUNOGENS, ANTIBODIES, TRACERS, ASSAY KITS AND METHODS FOR MAKING SAME | CAYMAN CHEMICAL COMPANY, INCORPORATED (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2011159740-A2 | METHODS FOR MANUFACTURING TETRANOR-PROSTAGLANDIN D, J, E, A AND F METABOLITES | CAYMAN CHEMICAL COMPANY, INCORPORATED (US) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021437-A1 | TETRANOR-PGDM/PGJM SPECIFIC IMMUNOGENS, ANTIBODIES, TRACERS, ASSAY KITS AND METHODS FOR MAKING SAME | PGM2, PGD, PTGDR | PPARG 518/4885PPARD 558/4885PPARA 2322/4885 |
| US-20120041229-A1 | METHODS FOR MANUFACTURING TETRANOR-PROSTAGLANDIN D, J, E, A AND F METABOLITES | PTGES, PTGDR, PTGIR | PPARG 361/4885PPARD 299/4885PPARA 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.